Today, on 13 April 2021, an extraordinary general meeting was held in Ascelia Pharma AB. A sum-mary of the adopted resolutions follows below. In light of the ongoing Covid-19 pandemic and in order to reduce the risk of infection spreading, the meeting was held only by advance voting (postal vote) in accordance with temporary legislation.
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
Resolution on approval of the board of directors’ resolution on directed issue of shares
The meeting resolved to approve the board of directors’ resolution of 17 March 2021 to increase the company’s share capital with not more than SEK 5,000,000 through the issue of not more than 5,000,000 ordinary shares. Through the directed issue of shares, the company will receive SEK 200 million before transaction costs. The net proceeds are intended to be used for (i) financing the Phase 2 study for the oral chemotherapy drug candidate Oncoral, (ii) accelerating activities towards the commercialization of the diagnostic drug Mangoral, currently in an ongoing Phase III study and (iii) general corporate purposes.